24 Jun 2021 Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Randomized Phase 2 ARC-7 Study
23 Jun 2021 Alfasigma acquires the European license for bentracimab from PhaseBio
23 Jun 2021 DARZALEX® (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma
23 Jun 2021 ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
22 Jun 2021 Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clinical Development Against COVID-19
22 Jun 2021 Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford
22 Jun 2021 Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
22 Jun 2021 Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510, Receives Approval for Clinical Trial in France
22 Jun 2021 LEO Pharma announces European Commission approval of Adtralza® (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
22 Jun 2021 Xentria Announces the Initiation of a Clinical Trial for XTMAB-16 for the Treatment of Sarcoidosis
22 Jun 2021 Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
22 Jun 2021 GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab
18 Jun 2021 Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
17 Jun 2021 Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab
17 Jun 2021 Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors
17 Jun 2021 BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
17 Jun 2021 Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
17 Jun 2021 MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
17 Jun 2021 Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC
17 Jun 2021 Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
16 Jun 2021 REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
16 Jun 2021 Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting
15 Jun 2021 Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434
14 Jun 2021 Debiopharm's CD37 Antibody Drug Conjugate Shows Promising Phase II Results for the Treatment of B-Cell Malignancies
14 Jun 2021 Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up